Adjunct Professor Emory University School of Medicine
|
|
- Agnes Parks
- 6 years ago
- Views:
Transcription
1 Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy to the Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct Professor Emory University School of Medicine
2
3 Organic (or primary), if there is an intrinsic valve disease Functional (or secondary), if the valve is structurally normal but leaks as a result of an extravalvular abnormality, such as an alteration in LV chamber geometry and/or dilatation of the mitral annulus that adversely affects normal coaptation of the mitral valve leaflets during systole Ischemic MR may be organic (ruptured or ischemic papillary muscle) and/or functional because of LV chamber dilatation Nonischemic MR may be organic (e.g., rheumatic) or functional (e.g., dilated cardiomyopathy)
4
5
6
7
8
9
10 Percutaneous Mitral Repair Caution: Investigational Device. Limited by Federal (US) Law to Investigational Use
11
12 1 clip 2 clips
13 Key Anatomic Eligibility Criteria Journal of the American College of Cardiology, Volume 54, Issue 8, 2009,
14
15 EVEREST I & II EVEREST II ONLY Ted Feldman, EVEREST I PI, EVEREST II PI Evanston Northwestern Hospital, Evanston, Patrick L Whitlow The Cleveland Clinic, Cleveland, OH Hal Wasserman/Bill Gray Michael Rinaldi Columbia University, New York, NY; Danville, CT Sanger Clinic, Charlotte, NC Howard Herrmann Richard W Smalling University of Pennsylvania, Philadelphia, PA Houston Health Sciences Center, Houston, TX Bill Gray/Mark Reisman Peter Block/Ziyad Ghazzal Swedish Medical center, Seattle, WA Emory University Hospital, Atlanta, GA Paul Kramer Shawnee Mission Medical Center, Shawnee Mission, KS Steven Bailey University of Texas Health Sciences Center, San Antonio, Andrew C Eisenhauer Brigham and Women Hospital, Boston, MS Saibal Kar Cedars Sinai Medical Center, Los Angeles, CA James Hermiller The Care Group, Indianapolis, IN Tanvir Bajwa St. Luke s Medical Center, Milwaukee, WI Vish Bhoopalam Nebraska Heart Institute, Lincoln, NE Andrew Berke Tim Byrne St. Francis Hospital, Long Island, NY Banner Good Samaritan Medical Center, Phoenix, AZ John Carroll University of Colorado, Denver, CO Peter Fail Terrebonne General Medical Center, Houma, LA Eric Fretz Victoria Heart Institute Foundation, Victoria BC, Canada Paul Grayburn Kenny Kent Baylor Univrsity Medical Center, Dallas, TX Washington Hospital Center, Washington DC Robert Kipperman John Lasala Oklahoma Heart Hospital, Okalahoma City, OK Washington University Medical Center, St. Louis, MO D. Scott Lim University of Virginia, Charlottesville, VA Reginald Low University of California at Davis, Sacramento, CA James Maddux/Mark Sanz St. Patrick's Hospital & Health Science Center, Missoula, M Michael O'Donnell St. Joseph s Mercy Hospital, Ypsilanti, MI Wesley Pedersen Minneapolis Heart Institute, Minneapolis, MN Stephen R Ramee Eric Horlick Ochsner Clinic Foundation, New Orleans, LA Toronto General Hospital, Toronto, ON, Canada James Slater Andrew Wang NYU Medical Center, New York, NY Duke University, Durham, NC Brian Whisenant Latter Day Saints Hospital, Salt Lake City, UT Chiu Wong Cornell Weill Medical Center, New York, NY George Hanzel William Beaumont Hospital, Royal Oak, MI Raymond Leung Ramon Quesada Royal Alexandra Hospital, Edmonton, AB, Canada Baptist Hospital of Miami, Miami, FL Elyse Foster, Echocardiographic Core Laboratory University of California at San Francisco, San Francisco, CA Donald D Glower, EVEREST II Co-PI (Surgery) Duke University, Durham, NC
16
17
18 At 4 years, the rate of the composite endpoint of freedom from death, surgery, or 3+ or 4+ MR in the intention-to-treat population was 39.8% in the percutaneous repair group versus 53.4% in the surgical groups (p<0.070)
19 Death were 17.4% versus 17.8% (p=0.914) 3+ or 4+ MR was present in 21.7% versus 24.7% (p=0.745) at 4 years of follow-up, respectively Surgery for mitral valve dysfunction, however, occurred in 20.4% versus 2.2% (p < 0.001) at 1 year and 24.8% versus 5.5% (p < 0.001) at 4 years
20 Patients treated with percutaneous repair of the mitral valve more commonly required surgery to treat residual MR However, after the first year of follow-up, there were few surgeries required after either percutaneous or surgical treatment and no difference in the prevalence of moderatesevere and severe MR or mortality at 4 years
21 ACCESS-EUROPE Phase I A Post Market Study of the MitraClip System for the Treatment of Significant Mitral Regurgitation in Europe: Analysis of Outcomes at 1 Year Wolfgang Schillinger, MD on behalf of the ACCESS EU investigators European Society of Cardiology Congress 2012 Munich, Germany
22 Demographics and Co-morbidities EVEREST II RCT Device Patients N=178 EVEREST II High Surgical Risk Cohort N=211 ACCESS EU MitraClip Patients N=567 Mitral Regurgitation Grade 3+, (%) Ejection Fraction < 40%, (%) Functional MR, (%) Ischemic NA NA 42 Non-ischemic NA NA 58 Degenerative MR, (%)
23 30 Days 97.4% 95.6% 96.6% 1 Year 86.4% 76.3% 81.8% p<0.05 Logistic EuroSCORE <20% (N=314) Logistic EuroSCORE 20% (N=253) All Patients (N=567) At Risk 0 Day 30 Days 180 Days 360 Days All Patients Logistic EuroSCORE <20% Logistic EuroSCORE 20%
24 27 patients (4.8%): Single leaflet device attachment. All but 1 case were diagnosed within 6 months from the index procedure. 10 underwent a second MitraClip procedure, no action was taken in 11 patients, 6 patients had mitral valve repair or replacement surgery, and 1 patient had additional MitraClip devices implanted during the index procedure. There have been no reports of MitraClip device embolization in the ACCESS-EU Study.
25 Thirty-six subjects (6.3%) underwent a mitral valve surgery within 12 months after the MitraClip implant procedure. Nineteen patients (3.4%) underwent a second intervention to place an additional MitraClip device to reduce MR. Of the 19 attempts to further reduce MR with a second intervention to place a MitraClip device, 14 (74%) were successful.
26
27 The MitraClip device (Abbott Vascular, Santa Clara, California) was approved October 24, 2013, for the reduction of significant ( 3+), symptomatic, degenerative MR in highly anatomically selected patients considered by an experienced heart team to be at prohibitive risk for mitral valve surgery.
28 Mod/severe MR Etiology: Degenerative (prolapse); ischemic(+/-) with non-dilated annulus functional (if annulus <4.5cm) Central jet of MR (A2/P2) LVEF > 30% No LA thrombus NSR helps but not necessary Must have reason to repair MR --- ( LV dilation, development of AF, symptoms)
29
30 World-class Training & Regular use Produce Excellent Learning Curves Device Times - UKE Hamburg, DE Device Time 6:00 4:48 3:36 2:24 1:12 0: Implants - blue 1 clip, white 2 clips Avg. 1 clip 1:20 2 clips 1:55 Device Times - Ospedale Ferrarato, Catania, IT 3:21 Avg. 1 clip 1:00 2 clips 2:04 Device Time 2:52 2:24 1:55 1:26 0:57 0:28 0: Implants - blue 1 clip, white 2 clips
31
32
33
34
35 European Heart Journal (2015) 36, 1651
36 Leaflets Annulus Supporting structures Left ventricle
37 Discontinuation of the mitral-ventricular continuity results in maladaptive remodelling and impaired LV performance The mitral valve regulates the flow pattern within the LV Preservation of anterior leaflet mobility and asymmetric flow may be associated with better LV performance
38
39 CARILLON Mitral Contour System Designed to be positioned, adjusted, and gently anchored in the coronary sinus/great cardiac vein to reshape the annulus around the mitral valve to reduce mitral regurgitation
40 53 patients were enrolled 36 patients underwent successful permanent device implantation. Significant benefit in reductions in quantitative measures of functional MR Positive clinical outcomes: improvement in 6-min walk test, functional class, and quality of life In 17 of the 53 patients, the device could not be permanently implanted, due to difficulty cannulating the coronary sinus, ineffective reduction in MR, or compression of a coronary artery. The Carillon device received CE mark approval in Europe in 2011.
41 Is the Coronary Sinus the answer? or the question? The CS problem Annular plane
42 Valtech Cardioband CE mark approved
43
44 CARDIOBAND European Heart Journal (2015) 36, 1651
45 Valtech Cardioband 40 high-risk patients with significant secondary MR 93% had NYHA class III-IV symptoms, with a mean LV ejection fraction of 33.3%. Acute procedural success, defined as successful implantation with acute MR reduction to grade < 2+, was achieved in all but three patients (92%).
46 Valtech Cardioband At 30 days, the mortality rate was 5.0%. None of the deaths were considered device-related. NYHA Class I-II at 6 months (80%) and 12 months (70%) MR grade 2+ (85% and 94% at 6 and 12 months, respectively). Improvements in quality of life as assessed with the Minnesota Living With Heart Failure Questionnaire
47 Figure 6. Direct annular plication concept. Masson J, Webb J G Circ Cardiovasc Interv 2009;2: Copyright American Heart Association
48
49 CE mark approval is expected 51 patients with moderate to severe functional mitral regurgitation LVEF 34±8% 30-day rates for all-cause mortality, stroke and myocardial infarction were 2.8%, 5.9% and 2.0%, respectively; the six-month death rate was 12.2%. Echocardiography: significant reduction of anterior-posterior and septal-lateral dimensions of the mitral annulus
50 Implanted pledget
51
52 CardiAQ Prosthesis Chiam, P. T. L. et al. J Am Coll Cardiol Intv 2011;4:1-13 Copyright 2011 American College of Cardiology Foundation. Restrictions may apply.
53
54
55 European Heart Journal (2015) 36, 1651
56 Comparison of transcatheter mitral valve implantation and transcatheter mitral valve repair European Heart Journal (2015) 36, 1651
Disclosure Statement of Financial Interest Saibal Kar, MD, FACC
MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
More informationPercutaneous Repair for MR:
Percutaneous Repair for MR: Follow-up and longer term outcomes Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital 16th ANGIOPLASTY SUMMIT TCT Asia Pacific 2011 April 27-29 th Seoul, Korea Ted Feldman
More informationOutline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines
Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More informationPrognostic Impact of FMR
Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years From Medical Therapy to Surgical Repair to Transcatheter Intervention The Interventionalist s View Samin K Sharma, MD, FACC, FSCAI Director
More informationStatus Of The MitraClip: Trials (EVEREST II & COAPT) & FDA
Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas, Nevada December 8 11 th, 2013 Ted Feldman MD, FACC, FESC,
More informationPercutaneous Mitral Valve Repair
Indiana Chapter of ACC November 15 th,2008 Percutaneous Mitral Valve Repair James B Hermiller, MD, FACC The Care Group, LLC St Vincent Hospital Indianapolis, IN Mechanisms of Mitral Regurgitation Mitral
More informationPercutaneous Treatment of Mitral Insufficiency: Present and Future
Percutaneous Treatment of Mitral Insufficiency: Present and Future Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine Seattle, WA
More informationACCESS-EUROPE Phase I
ACCESS-EUROPE Phase I A Post Market Study of the MitraClip System for the Treatment of Significant Mitral Regurgitation in Europe: Analysis of Outcomes at 1 Year Wolfgang Schillinger, MD on behalf of the
More informationCurrent status: Percutaneous mitral valve therapy
Current status: Percutaneous mitral valve therapy Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital ESC Stockholm 2010 Disclosures Research Grants Abbott, Edwards Consultant Abbott, Edwards 2 Percutaneous
More informationPercutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat
Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,
More informationIntroducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
More informationPercutaneous mitral valve repair: current techniques and results
Percutaneous mitral valve repair: current techniques and results Ted Feldman, M.D., FSCAI, FACC Angioplasty Summit April 25-27 th th 2007 Seoul, Korea Ted Feldman MD, FACC, FSCAI Disclosure Information
More informationGDMT for percutaneous mitral valve repair
GDMT for percutaneous mitral valve repair Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital The 11th Annual Innovations & Trends in Cardiovascular Care New Brunswick, NJ October 18 th 2014 Ted Feldman
More informationRandomized Comparison of Percutaneous Mitral Valve Repair and Surgery for Mitral Regurgitation
Randomized Comparison of Mitral Valve Repair and for Mitral Regurgitation 2 Year Results of the EVEREST II Randomized Controlled Trial Ted Feldman, Elyse Foster, Saibal Kar, William Gray, Andrew Wang,
More informationChapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine
Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the
More informationMitral Regurgitation
Mitral Regurgitation Focus on Percutaneous Repair Steven J. Yakubov, MD FACC FSCAI System Chief, Structural Heart Diseaese, OhioHealth John H. McConnell Chair of Advanced Structural Heart Disease Medical
More informationCatheter-based mitral valve repair MitraClip System
Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular
More informationTranscatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health
Transcatheter Mitral Innovations, Part II Michael Mack, M.D. Baylor Scott & White Health Conflict of Interest Disclosure Co-PI of the COAPT Trial of MitraClip sponsored by Abbott Vascular Uncompensated
More informationTranscatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT
Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT and Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac
More informationBurden of Mitral Regurgitation (MR) in the US Why is This Important?
Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence
More informationPercutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today?
Percutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today? Peter S. Fail, MD, FACC, FACP, FSCAI Director of the Cardiac Catheterization Laboratories and Interventional
More informationEulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain
Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain Device Landscape 2010 PERCUTANEOUS TECHNIQUES Percutaneous indirect annuloplasty Percutaneous direct annuloplasty Edge to Edge ( E-Valve ) Non
More informationOutcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.
ACC 2015 LBCT Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S. A report from the STS/ACC TVT Registry Paul Sorajja, MD, Saibal Kar, MD, Amanda Stebbins,
More informationPercutaneous mitral valve repair/replacement. Jan Van der Heyden MD, PhD St.Antonius Hospital Nieuwegein
Percutaneous mitral valve repair/replacement Jan Van der Heyden MD, PhD St.Antonius Hospital Nieuwegein Mitral Valve anatomy Difference between AoV and MV Aortic Valve Mitral Valve Transcatheter Mitral
More informationThe Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System
The Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System A prospective, multicenter, non randomized study to evaluate the safety and efficacy of the Medtronic AVE Driver Coronary Stent
More informationPERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL
PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL DISCLOSURES I WILL BE DISCUSSING OFF-LABEL USAGE OF DEVICES RELATED TO TMVR OBJECTIVES
More informationCLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;
CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ; Επιµορφωτικά Σεµινάρια Ειδικευοµένων Καρδιολογίας 7 Απριλίου 2012 M Chrissoheris MD FACC THV Department HYGEIA Hospital Degenerative MR (DMR) Usually refers to an anatomic
More informationNext Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationTREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC
TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS
More informationInvestigational Device only in the U.S. Not available for sale in the U.S. ACCESS EU European Society of Cardiology
Early hemodynamic and echocardiographic outcomes after percutaneous MitraClip therapy in patients with mitral regurgitation. Preliminary results of the MitraClip arm of the ACCESS EUROPE registry. Jörg
More informationAlec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France
Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat
More informationTranscatheter Mitral Valve Replacement How Close Are We?
Transcatheter Mitral Valve Replacement How Close Are We? Gregory Pavlides, MD, PhD, FACC, FESC Professor of Medicine Miscia Chair of Interventional Cardiology Director, Cardiac Catheterization Laboratories,
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationOrganic mitral regurgitation
The best in heart valve disease Organic mitral regurgitation Ewa Szymczyk Department of Cardiology Medical University of Lodz, Poland I have nothing to declare Organic mitral regurgitation leaflet abnormality
More informationSURGICAL AND TRANSCATHETER MITRAL VALVE REPLACEMENT VS. REPAIR: COMPETITION OR SYNERGY
SURGICAL AND TRANSCATHETER MITRAL VALVE REPLACEMENT VS. REPAIR: COMPETITION OR SYNERGY Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research
More informationPercutaneous mitral annuloplasty. Francesco Maisano MD, FESC San Raffaele Hospital Milano, Italy
Percutaneous mitral annuloplasty Francesco Maisano MD, FESC San Raffaele Hospital Milano, Italy Disclosure Consultant for Abbott, Medtronic, St Jude, Edwards, ValtechCardio Founder of 4Tech Surgical techniques
More informationPercutaneous Mitral Valve Therapies
Percutaneous Mitral Valve Therapies Jeffrey J. Popma, MD Director, Interventional Cardiology Clinical Services Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard Medical School
More informationGet Ready for Percutaneous Mitral Valve Approaches
Get Ready for Percutaneous Mitral Valve Approaches Paul A. Grayburn, MD Baylor Scott and White Healthcare System The Heart Hospital Baylor Plano and Baylor Heart and Vascular Hospital Dallas, TX HOPE Unmet
More information8/31/2016. Mitraclip in Matthew Johnson, MD
Mitraclip in 2016 Matthew Johnson, MD 1 Abnormal Valve Function Valve Stenosis Obstruction to valve flow during that phase of the cardiac cycle when the valve is normally open. Hemodynamic hallmark - pressure
More informationAATS Annual Meeting Seattle, WA Irving Kron, M.D. Professor and Chairman Department of Surgery University of Virginia Hospital Charlottesville,
AATS Annual Meeting Seattle, WA Irving Kron, M.D. Professor and Chairman Department of Surgery University of Virginia Hospital Charlottesville, Virginia AATS Ischemic MR Guideline Writing Group Roster
More informationΤελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ
Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ Carpentier MV Classification- Leaflet Mobility Normal Increased Decreased Mobility
More informationTranscatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M.
Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott Chairperson: M. Haude Panellists: A. Al Nooryani, M. Al Otaiby Session objectives To learn about the clinical patient profile for
More informationMitraClip World Wide Commercial Experience
MitraClip World Wide Commercial Experience Valves Repaired. Lives Improved. Carlos G. Hernandez, MBA Sr. Product Manager, Strategic Planning Abbott Vascular October, 2014 MitraClip Transcatheter Mitral
More informationMitral Valve Disease. James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN
Mitral Valve Disease James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN Disclosures Affiliation/Financial Relationship Consulting Fees/Honoraria Speaker Bureau Company Abbott, BSC,
More informationTranscatheter Mitral Valve Interventions: Clinical Indications. Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France.
Transcatheter Mitral Valve Interventions: Clinical Indications Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France. Conflicts of interest: -Consultant for Medtronic -Consultant for Cephea Anatomy of
More informationTranscatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President
Transcatheter Mitral & Tricuspid Therapies Bernard J. Zovighian Corporate Vice President We Will Lead and Transform Treatment for Patients with Mitral and Tricuspid Diseases Mitral and Tricuspid Diseases
More informationUpdate on Transcatheter Mitral Valve Repair and Replacment
Update on Transcatheter Mitral Valve Repair and Replacment Vinod H. Thourani, MD Professor of Surgery Chair, Department of Cardiac Surgery Medstar Heart and Vascular Washington Hospital Center Georgetown
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair Policy Number: Original Effective Date: MM.06.027 08/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/01/2017 Section: Surgery Place(s)
More informationWho will Benefit from Percutaneous Management of Mitral Regurgitation? An Imaging Guide to Management
Who will Benefit from Percutaneous Management of Mitral Regurgitation? An Imaging Guide to Management James D. Thomas, M.D., F.A.C.C. Department of Cardiovascular Medicine Heart and Vascular Institute
More informationFunctional Mitral Regurgitation; therapeutic continuum overview. Michele Senni. Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII
Functional Mitral Regurgitation; therapeutic continuum overview Michele Senni Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII Functional Mitral Regurgitation FMR is not the result
More informationTranscatheter Aortic Valve Replacement with a Repositionable Self-expanding Bioprosthesis in Patients With Severe Aortic Stenosis Suboptimal for
Transcatheter Aortic Valve Replacement with a Repositionable Self-expanding Bioprosthesis in Patients With Severe Aortic Stenosis Suboptimal for Surgery: One-Year Results from the Evolut R US Pivotal Study
More informationCite this article as:
doi: 10.21037/acs.2018.09.05 Cite this article as: Cheung A. Early experience of TIARA transcatheter mitral valve replacement system.. doi: 10.21037/acs.2018.09.05 This is a PDF file of an edited manuscript
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationIschemic Mitral Regurgitation
Ischemic Mitral Regurgitation 1 / 6 2 / 6 3 / 6 Ischemic Mitral Regurgitation Background Myocardial infarction (MI) can directly cause (IMR), which has been touted as an indicator of poor prognosis in
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationWhat Is the Role of Mitral Repair in Heart Failure?
ASK THE EXPERTS What Is the Role of Mitral Repair in Heart Failure? Experts discuss treatment strategies for patients with mitral regurgitation progressing to heart failure. WITH WILLIAM WEIR, MD; STEPHEN
More informationManagement of Secondary MR : Insights from CTSN Ischemic MR trial; COAPT and MITRA-FR:
Management of Secondary MR : Insights from CTSN Ischemic MR trial; COAPT and MITRA-FR: Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute,
More informationProtection Devices for Stroke Prevention Do the Data support their Routine Use?
ACC 2015 San Diego, March 14-16 nd, 2015 Protection Devices for Stroke Prevention Do the Data support their Routine Use? Eberhard Grube MD, FACC University Hospital, Dept of Medicine II, Bonn, Germany
More informationMitral Regurgitation Epidemiology and Classification
Subject: Transcatheter Mitral Valve Repair Page: 1 of 23 Last Review Status/Date: December 2015 Transcatheter Mitral Valve Repair Description Transcatheter mitral valve repair is a potential alternative
More informationMitraClip in the ICCU: Which Patient will Benefit?
MitraClip in the ICCU: Which Patient will Benefit? DAVID MEERKIN STRUCTURAL A ND CONGENITAL HEART DISEASE UNIT SHAARE ZEDEK MEDICAL CENTER JERUSALEM Conflict of Interest No relevant disclosures Complex
More informationHealth Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial
Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial Suzanne V. Arnold, MD, MHA Saint Luke s Mid America
More informationReshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid
Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid Patient records 76 y.o. male Hypertension. Dyslipidemia. OPLD. Smoked in the past. Diabetes
More informationCardioband: una chance per l insufficienza mitralica funzionale
HEARTLINE Genova 10-11 novembre 2017 Cardioband: una chance per l insufficienza mitralica funzionale Sergio Berti Ospedale del Cuore Fondazione C.N.R. Reg Toscana Massa/Pisa Reduction of Septo Lateral
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationDegenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention
Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention John N. Hamaty D.O. FACC, FACOI November 17 th 2017 I have no financial disclosures Primary Mitral
More informationClinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients
Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients Susheel Kodali, MD on behalf of The PARTNER Trial Investigators
More informationMitral regurgitation (MR) is the most common
The EVEREST Percutaneous Mitral Leaflet Repair Trials An overview of the safety and efficacy data of the MitraClip system for treating mitral regurgitation. BY ALICE PERLOWSKI, MD, AND TED E. FELDMAN,
More informationEdwards' solution for patients suffering from tricuspid valve disease
Edwards' solution for patients suffering from tricuspid valve disease R. S. von Bardeleben, MD Head Structural and Heart Valve Center Heart Center Cardiology I, University Medicine Mainz Germany Potential
More informationZhiwei Zhang, Ph.D. National Opinion Research Center
Drug and Alcohol Use and Related Matters Among Arrestees 2003 Zhiwei Zhang, Ph.D. National Opinion Research Center Acknowledgement This publication was developed for the National Institute of Justice (NIJ),
More informationProfessor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017
James S. Gammie, MD Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical The Houston Aortic Symposium February 2-25, 2017 Disclosure Statement of Financial Interest Within
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationUnderstanding the guidelines for Interventions in MR. Ali AlMasood
Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe
More informationUse of MitraClip Beyond Everest Criteria
Use of MitraClip Beyond Everest Criteria Takashi Matsumoto, MD Sendai Kousei Hospital Sendai, Japan No Disclosure of Financial Interest Introduction The efficacy and safety of the MitraClip therapy was
More informationNo Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs)
Units Used In Transplants/Infusions No Other Company Discloses Higher Transplant Survival Rate Family Banking Provides Exclusive Access To Emerging Treatments With Your Own Cells 175 85% Type 1 Diabetes
More informationWhat echo measurements are key prior to MitraClip?
APHP CHU Bichat - Claude Bernard What echo measurements are key prior to MitraClip? Eric Brochet,MD Cardiology Department Hopital Bichat Paris France No disclosure Conflict of interest Case 69 y.o man
More informationIndex. B B-type natriuretic peptide (BNP), 76
Index A ACCESS-EU registry, 158 159 Acute kidney injury (AKI), 76, 88 Annular enlargement, RV, 177 178 Annuloplasty chordal cutting, 113 complete ring, 99 etiology-specific ring, 100 evolution, 98 flexible
More informationManagement of HOCM: Non-Surgical Options
Management of HOCM: Non-Surgical Options Howard C. Herrmann, MD, FACC, MSCAI John Bryfogle Professor of Cardiovascular Medicine and Surgery Health System Director for Interventional Cardiology Director,
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationVolunteering in Oklahoma City, OK
6/17/2010 Oklahoma City Profile - Volunteering in information on volunteering and civic engagement Volunteering in Oklahoma City, OK Statistics for this area were collected within the Oklahoma City Metropolitan
More informationTranscatheter Mitral Valve for fmr: The Era of Too Many Options
Transcatheter Mitral Valve for fmr: The Era of Too Many Options Isaac George, M.D. Surgical Director, Structural Heart & Valve Center Assistant Professor of Surgery Columbia University Medical Center Disclosure
More informationAPOLLO TMVR Trial Update: Case Presentation
APOLLO TMVR Trial Update: Case Presentation Anelechi Anyanwu, MD, MSc, FRCS-CTh Professor and Vice-Chairman Department of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure
More informationNeoChord Mitral Valve Repair. Department of Cardiac, Thoracic and Vascular Sciences University of Padua, Italy
NeoChord Mitral Valve Repair Department of Cardiac, Thoracic and Vascular Sciences University of Padua, Italy Disclosures Proctoring for Neochord Inc. NeoChord procedure Transapical off-pump mitral valve
More informationTreatment for functional mitral regurgitation
Transcatheter Leaflet Repair for Functional MR What will randomized trials mean for the future of mitral intervention? BY TED FELDMAN, MD, FESC, FACC, MSCAI; PAUL SORAJJA, MD, FACC, FSCAI; PAUL GRAYBURN,
More informationReally Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients?
Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients? David H. Adams, MD Cardiac Surgeon-in-Chief Mount Sinai Health System Marie Josée and Henry R. Kravis Professor and
More informationSevere left ventricular dysfunction and valvular heart disease: should we operate?
Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict
More informationSASI Analysis of Funds Distributed in the United States By the Centers for Disease Control and Prevention (CDC) Pursuant to PS
SASI Analysis of Funds Distributed in the United States By the Centers for Disease Control and Prevention (CDC) Pursuant to PS17-1704 1 April 13, 2017 INTRODUCTION In the Summer of 2016, the Centers for
More informationMitral regurgitation (MR) is the second most
Current Options for Mitral Annuloplasty and Leaflet Repair The benefits and limitations of today s FDA- and CE Mark approved mitral repair technologies. BY ROBERT SCHUELER, MD, AND JAN-MALTE SINNING, MD,
More informationIoannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens
MITRAL REGURGITATION IN PATIENT WITH SEVERE AORTIC VALVE STENOSIS Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens I HAVE NOTHING TO DECLARE Management
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationTranscatheter mitral valve repair is considered investigational in all situations.
2.02.30 Transcatheter Mitral Valve Repair Section 2.0 Medicine Subsection 2.02 Cardiology Description Effective Date September 30, 20114 Original Policy Date September 30, 2014 Next Review Date September
More informationSteven F Bolling Professor of Cardiac Surgery University of Michigan
Optimal Treatment of Functional MR Steven F Bolling Professor of Cardiac Surgery University of Michigan Functional MR Functional MR in Ischemia Badhwar, Bolling, chapter in: Advances in Heart Failure,
More informationCase Report. Percutaneous Mitral Repair with MitraClip as an Adjunct Therapy of Heart Failure. Introduction. Case Report. Keywords
Percutaneous Mitral Repair with MitraClip as an Adjunct Therapy of Heart Failure Petherson Susano Grativvol, 1,2 Katiuska Massucatti Grativvol, 1,2 Alberto de Paula Nogueira Jr., 1,2 João Eduardo Tinoco
More informationSURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators ACC Late Breaking Clinical Trials March 16,
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More information2018 National Oncologists Workforce Study OCTOBER 2018
2018 National Oncologists Workforce Study OCTOBER 2018 Introduction Providers have long cautioned that the U.S. healthcare system is facing imminent physician shortages across many different specialties.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of percutaneous mitral valve leaflet repair for mitral regurgitation Mitral regurgitation
More informationRepair. Commercial Products Prior authorization is recommended for Commercial Products.
Medical Coverage Policy Transcatheter Mitral Valve Repair EFFECTIVE DATE: 11 01 2018 POLICY LAST UPDATED: 06 19 2018 OVERVIEW Transcatheter mitral valve repair (TMVR) is an alternative to surgical therapy
More informationEcho in Asymptomatic Mitral and Aortic Regurgitation
2017 ASE Florida Orlando, FL October 9, 2017 10:40 11:00 PM 20 min Grand Harbor Ballroom South Echo in Asymptomatic Mitral and Aortic Regurgitation Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology
More information